704. Klebsiella pneumoniae Carbapenemase and Verona Integron-Encoded Metallo-Beta-Lactamase among Carbapenem-Resistant Enterobacteriaceae in Kentucky
Session: Poster Abstract Session: Resistance Mechanisms: Gram-Negative
Thursday, October 4, 2018
Room: S Poster Hall
Posters
  • IDWeek_poster-704_Spicer.pdf (552.9 kB)
  • Background: Klebsiella pneumoniae carbapenemase (KPC) and Verona integron-encoded metallo-β-lactamase (VIM) have been the most commonly identified carbapenemases among carbapenemase-producing carbapenem-resistant Enterobacteriaceae (CP-CRE) in Kentucky since 2013. Understanding the frequency and epidemiology of these CP-CRE can help inform prevention strategies.

    Methods: We reviewed reports of KPC- and VIM-producing CRE from January 2013 through December 2017. CRE became reportable in Kentucky in February 2015 and statewide request to laboratories and healthcare facilities for isolate submission for mechanism testing was made in September 2017. Prior to that time, mechanism testing for CRE was conducted at a limited number of laboratories or during outbreak investigations. Demographic data included age, sex, and inpatient or outpatient status. Descriptive analyses were performed.

    Results: As of December 31, 2017, a total of 156 CP-CRE isolates had been identified (124 KPC, 31 VIM, 1 NDM), with an increase from 2013 (n=13) to 2017 (n=48). KPC was identified in isolates from 124 patients; VIM was identified in isolates from 26 patients, with 4 patients (15%) having multiple organisms with the mechanism. KPC was identified most commonly from Klebsiella pneumoniae (57/124, 46%); VIM was identified most commonly from Enterobacter cloacae (14/31, 45%). KPC was found in 6 different Enterobacteriaceae genera; VIM in 4. KPC-producing CRE were identified in 22 acute-care and long-term acute-care facilities in 14 counties, with 9 reporting >2 isolates. Fifteen percent (19/124) of KPC-producing CRE were isolated from outpatients. VIM-producing CRE were identified in 2 acute-care facilities located in two urban areas; 1 was from an outpatient. Patients with VIM were younger than those with KPC (43 versus 60 years, p < 0.001).

    Conclusion: KPC is the predominant carbapenemase in Kentucky and is more widely disseminated than VIM, which has been limited to two facilities. CRE reporting and mechanism testing have yielded a greater understanding of regional CRE epidemiology and has the potential to facilitate response efforts to slow further spread.

    Kevin Spicer, MD, PhD, MPH1, Lynn Roser, PhD, RN, CIC2 and Andrea Flinchum, MPH, BSN, CIC2, (1)Prevention and Response Branch, Centers for Disease Control & Prevention, Division of Healthcare Quality Promotion, Frankfort, KY, (2)Epidemiology, Healthcare-Associated Infection Prevention Program, Kentucky Department for Public Health, Frankfort, KY

    Disclosures:

    K. Spicer, None

    L. Roser, None

    A. Flinchum, None

    Findings in the abstracts are embargoed until 12:01 a.m. PDT, Wednesday Oct. 3rd with the exception of research findings presented at the IDWeek press conferences.